Company Profile

Pro Actina Sa Is A Research Driven And Innovation Focused Clinical Stage Smefounded In 2006 In Athens Greecepro Actina Started Its Operation As A Contract Research Organisationoffering Chemistry Services To Pharma And Biotech Companies Worldwideduring The Past Yearsthrough The Establishment Of Collaborations With The Academiaindustry And Other Smesthe Company S Activities Have Been Shifted To The Diagnosticsbiomarker Field And Thesme Instrument Aegrant Awarded In 2015 Gave The Boost Towards This Direction Pro Actina S Vision Is To Become A Leader In The Diagnostics For Brain Abnormalities By Building In House Expertise And By Establishing Strategic Collaborations For The Development Of Novel Non Invasive Diagnostic Toolsour Mission Is To Provide Patients And Doctors With Innovativecost Effective Diagnostic Solutions As Integrated Parts Of Precision Medicine Approaches Pro Actina Is Currently Partnering With Both Academia And Industry For The Implementation Of Gliomarkahorizon 20204 Year Project For The Clinical Validation Of An In Vivo Biomarker For Brain Tumourgliomadiagnosisthe End Product Will Consist Of A Diagnostic Radiopharmaceutical Kitcontaining Tetrofosminfor Single Photon Emission Computed Tomographyspectrepositionedby Both Clinical & Pharmaceutical Developmentspecifically For Brain Imagingthis Non Invasive Diagnostic Technique Will Provide Reliable Glioma Diagnosis With High Sensitivity & Specificity Aiming To Reduce The Need For Invasive And Costly Biopsyorphan Drug Designation Has Been Granted By Ema For Tetrofosmin For The Diagnosis Of Gliomathus Ensuring 10 Years Of Market Exclusivitythe End Product Is Expected To Be Ready For Marketing Authorisation Application To Ema By 2021For More Information Seewww Gliomark Eu